David A. Siegel Pacific Biosciences Of California, Inc. Transaction History

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Pacific Biosciences Of California, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 25,000 shares of PACB stock, worth $44,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares

25,000

Previous 102,500 75.61%

Holding current value

$44,000

Previous $120,000 74.17%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$0.91 - $1.45 $70,525 - $112,375	-77,500 Reduced 75.61%	25,000 $31,000
Q1 2025 May 15, 2025	SELL	$1.14 - $2.1 $74,556 - $137,340	-65,400 Reduced 38.95%	102,500 $120,000
Q4 2024 Feb 14, 2025	BUY	$1.55 - $2.65 $43,090 - $73,670	27,800 Added 19.84%	167,900 $307,000
Q3 2024 Nov 14, 2024	BUY	$1.2 - $2.17 $21,480 - $38,843	17,900 Added 14.65%	140,100 $238,000
Q2 2024 Aug 14, 2024	SELL	$1.36 - $3.65 $30,192 - $81,030	-22,200 Reduced 15.37%	122,200 $167,000
Q1 2024 May 15, 2024	SELL	$3.52 - $9.59 $26,048 - $70,966	-7,400 Reduced 4.87%	144,400 $541,000
Q4 2023 Feb 14, 2024	SELL	$5.97 - $10.36 $134,922 - $234,136	-22,600 Reduced 12.96%	151,800 $1.49 Million
Q3 2023 Nov 14, 2023	SELL	$8.23 - $13.93 $167,892 - $284,172	-20,400 Reduced 10.47%	174,400 $1.46 Million
Q2 2023 Aug 14, 2023	BUY	$9.97 - $14.05 $301,094 - $424,310	30,200 Added 18.35%	194,800 $2.59 Million
Q1 2023 May 15, 2023	SELL	$7.94 - $12.02 $177,856 - $269,248	-22,400 Reduced 11.98%	164,600 $1.91 Million
Q4 2022 Feb 14, 2023	SELL	$5.67 - $11.2 $4.51 Million - $8.92 Million	-796,000 Reduced 80.98%	187,000 $1.53 Million
Q3 2022 Nov 14, 2022	SELL	$3.93 - $8.57 $10.2 Million - $22.3 Million	-2,597,600 Reduced 72.55%	983,000 $5.71 Million
Q2 2022 Aug 15, 2022	BUY	$4.02 - $10.43 $10 Million - $26 Million	2,492,300 Added 229.01%	3,580,600 $15.8 Million
Q1 2022 May 16, 2022	BUY	$8.43 - $20.9 $5.95 Million - $14.8 Million	705,900 Added 184.6%	1,088,300 $9.9 Million
Q4 2021 Feb 14, 2022	SELL	$19.26 - $30.08 $3.44 Million - $5.37 Million	-178,400 Reduced 31.81%	382,400 $7.82 Million
Q3 2021 Nov 15, 2021	BUY	$24.86 - $35.02 $1.33 Million - $1.87 Million	53,500 Added 10.55%	560,800 $14.3 Million
Q2 2021 Aug 16, 2021	BUY	$22.3 - $36.02 $6.14 Million - $9.92 Million	275,500 Added 118.85%	507,300 $17.7 Million
Q1 2021 May 17, 2021	BUY	$26.38 - $51.15 $6.11 Million - $11.9 Million	231,800 New	231,800 $7.72 Million
Q1 2020 May 15, 2020	SELL	$2.36 - $5.26 $39,176 - $87,316	-16,600 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$4.6 - $5.57 $101,199 - $122,540	-22,000 Reduced 56.99%	16,600 $85,000
Q3 2019 Nov 14, 2019	SELL	$4.99 - $6.16 $933,130 - $1.15 Million	-187,000 Reduced 82.89%	38,600 $199,000
Q2 2019 Aug 14, 2019	BUY	$5.92 - $7.41 $1.34 Million - $1.67 Million	225,600 New	225,600 $1.37 Million
Q1 2018 May 15, 2018	SELL	$2.05 - $3.23 $62,934 - $99,161	-30,700 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$2.59 - $5.44 $31,080 - $65,280	12,000 Added 64.17%	30,700 $81,000
Q3 2017 Nov 14, 2017	BUY	$3.2 - $5.57 $59,840 - $104,159	18,700	18,700 $98,000

Others Institutions Holding PACB

# of Institutions

245

Shares Held

202M

Call Options Held

879K

Put Options Held

847K

View Full List

About PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Ticker PACB
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 224,840,992
Market Cap $396M
Description
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits design...

More about PACB

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account